Gordon M Y, Zola H
Transplantation. 1979 Feb;27(2):106-9. doi: 10.1097/00007890-197902000-00008.
Antilymphocyte sera (ALS) were prepared by different methods and examined for their myelotoxicity by bone marrow colony-forming assay, both before and after absorption with B cell antigens. The results show that myelotoxicity can readily be removed from some, but not all, ALS. The source of antigen and the immunisation protocol used determine the degree of myelotoxicity and hence the number of absorptions required. Non-myelotoxic ALS may be suitable for the prevention of graft-versus-host disease (GVHD) by in vitro treatment of bone marrow before transplantation.
采用不同方法制备抗淋巴细胞血清（ALS），并通过骨髓集落形成试验在与B细胞抗原吸附前后检测其骨髓毒性。结果表明，骨髓毒性可以从部分（而非全部）ALS中轻易去除。抗原来源和所用免疫方案决定了骨髓毒性程度，进而决定所需吸附次数。无骨髓毒性的ALS可能适用于在移植前对骨髓进行体外处理以预防移植物抗宿主病（GVHD）。
